The effect of serum activated ghrelin hormone on glycemic control in the diabetic patients with excessive body mass index

Year 2023, , 171 - 174, 31.05.2023

Yilmaz Fakı Semih Kalyon

https://doi.org/10.5472/marumj.1307861

Abstract

Objective: In the literature, plasma ghrelin level was found to be lower in patients with obesity or diabetes in a few studies. However,
there is no study comparing ghrelin level in non-diabetic and diabetic patients with overweight or obesity. We have two aims in this
study; first to show whether plasma ghrelin levels in type 2 diabetes mellitus patients with excessive body mass index (BMI) decrease
the level of a cumulative ghrelin which we expect in both diabetes-related and obesity-related conditions, secondly to study whether
there is a correlation between ghrelin level and diabetes complications.
Patients and Methods: Ethics committee decision and written informed consent from patients were received before the study. 57
BMI≥25 type 2 diabetic patients treated and followed up in the diabetic outpatient clinic and 25 BMI≥25 subjects without diabetes
mellitus (control group) were included in this case-control study. Pregnant women, patients with malignancy and under 18 years old
were excluded. The results were evaluated by the SPSS statistical program.
Results: The ghrelin and BMI values of the diabetic patients with excessive BMI and the non-diabetic patients with excessive BMI were
not statistically different. No statistical significant correlation between ghrelin and haemoglobin A1c (HbA1C), BMI, retinopathy,
neuropathy, albuminuria, and macrovascular complications was found in the type 2 diabetic patients with overweight or obesity.
Conclusion: The presence of diabetes in addition to patients with excessive BMI does not cause ghrelin levels to decrease more than
expected.

Keywords

Ghrelin, Diabetes Mellitus, Obesity, Overweight

References

• [1] Poher A, Tschöp MH, Müller TD. Ghrelin regulation of glucose metabolism. Peptides 2018;100:236-42. doi: 10.1016/j. peptides.2017.12.015
• [2] Nakazato M, Murakami N, Date Y, et al. A role for Ghrelin in the central regulation of feeding. Nature 2001;409:194-8. doi: 10.1038/35051587
• [3] Hashizume T, Horiuchi M, Tate N, et al. Effects of Ghrelin on growth hormone secretion from cultured adenohypophysial cells in cattle. Endocr J 2003;50:289-95. doi: 10.1016/s0739- 7240(02)00240-0
• [4] Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Grelin-a hormone with multiple functions. Front in Neuroend 2004;25:27-68. doi: 10.1016/j.yfrne.2004.03.002
• [5] Kojima M, Kangawa K. Grelin: structure and function. Physiol Rev 2005;85:495-522. doi : 10.1152/physrev.00012.2004
• [6] Aydin S, Ozkan Y, Caylak E, Aydin S. Grelin and its biochemical functions. Turkiye Klinikleri J Med Sci 2006;26:272-83.
• [7] Inui A. Ghrelin an somatotrophic signal from the stomach. Nat Rev Nuerosci 2001;2:551 – 60. doi : 10.1038/35086018
• [8] Akamizu T, Kangawa K. Translational research on the clinical aplications of Ghrelin. Endocr J 2006;53:585-91.
• [9] Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of Ghrelin expression in the stomach upon fasting insulin induced hypoglycemia and leptin administration. Biochem. Biophys. Res Commun 2001;281:1220-5. doi 10.1006/ bbrc.2001.4518
• [10] Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is dependent on nitric oxide. Peptides 2004;24:913 – 8. doi: 10.1016/s0196-9781(03)00160-8
• [11] Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227-32. doi: 10.2337/diabetes.50.2.227
• [12] Cummings DE, Weigle DS, Frayo RS, et al. Plasma Ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30. doi: 10.1056/ NEJMoa012908
• [13] Tscho¨p M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating Ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9. doi: 10.2337/ diabetes.50.4.707
• [14] Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M. Plasma Ghrelin levels in lean and obese humans and the effect of glucose on Ghrelin secretion. J Clin Endocrinol Metab 2002;87:240-4. doi : 10.1210/jcem.87.1.8129
• [15] Verdeş G, DuŢă CC, Popescu R, MituleŢu M, Ursoniu S, Lazăr OF. Correlation between leptin and Ghrelin expression in adipose visceral tissue and clinical-biological features in malignant obesity. Rom J Morphol Embryol 2017;58:923-9.
• [16] Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active Ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Europ J Endocrinol 2004;151: 573-7. boi: 10.1530/eje.0.1510573
• [17] Flanagan DE, Evans ML, Monsod TP, et al. The influence of insulin on circulating Ghrelin. Am J Physiol Endocrinol Metab 2003;284:313-6. doi : 10.1152/ajpendo.00569.2001
• [18] Griffen SC, Oostema K, Stanhope KL et al. Administration of lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses Ghrelin compared with regular/NPH insulin in female patients with type 1 diabetes. J Clin Endocrinol Metab 2006;91:485-91. doi:10.1210/jc.2005- 1338
• [19] Ueno H, Shiiya T, Mizuta M, Mondal MS, Nakazato M. Plazma Ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocrine J 2007;54:895-902. doi: https://doi.org/10.1507/ endocrj.K07-007
• [20] Kaçar AK, Saçan Ö, Öziçli N, Bolkent Ş, Yanardağ R, Bolkent S. The effects of Ghrelin on renal complications in newborn diabetic rats. Europ J Biol 2020;79;1-6.